trending Market Intelligence /marketintelligence/en/news-insights/trending/mfks5eR1FBPnbjfMKEP71w2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Flexion Therapeutics prices $122.4M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Flexion Therapeutics prices $122.4M common stock offering

Flexion Therapeutics Inc. priced an underwritten public offering of 4.8 million common shares at $25.50 apiece for expected gross proceeds of about $122.4 million.

The offering is expected to close Oct. 16, subject to customary closing conditions.

Flexion has also granted the underwriters an option to buy up to 720,000 additional shares.

The company plans to use the net proceeds to fund manufacturing and commercialization of Zilretta, which was recently approved by the U.S. Food and Drug Administration, to fund product pipeline development, and for working capital and general corporate purposes.

Wells Fargo Securities, BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers. Needham & Co. and Raymond James are acting as co-lead managers.